Use of tyramine for the preparation of a medicament for the prevention and / or treatment of contact dermatitis

By administering tyramine topically, the infiltration of immune cells and the accumulation of CD8+ tissue-resident memory T cells at the skin lesion site are inhibited, which solves the problem of recurrent allergic contact dermatitis and achieves safe and effective treatment and prevention.

CN123078465APending Publication Date: 2026-11-13SHANGHAI DERMATOLOGY HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611519325.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-28
Publication Date
2026-11-13

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively prevent and treat contact dermatitis, especially recurrent allergic contact dermatitis, and existing drugs have risks of side effects and treatment limitations.

Method used

Tyramine is used as the active ingredient. It is administered topically through the skin to inhibit the infiltration of immune cells and the accumulation of CD8+ tissue-resident memory T cells at the site of skin lesions, thereby alleviating dermatitis symptoms and improving pathological damage to skin tissue.

Benefits of technology

It significantly reduces dermatitis symptoms, lowers the risk of disease recurrence, improves pathological damage to skin tissue, has good safety profile, and does not affect the normal immune homeostasis of the skin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123078465A_ABST
    Figure CN123078465A_ABST
Patent Text Reader

Abstract

This invention provides the application of tyramine in the preparation of drugs for the prevention and / or treatment of contact dermatitis, belonging to the field of biomedical technology. This invention addresses the treatment challenges of contact dermatitis patients, such as difficulty in avoiding allergens, frequent relapses, and limited choices of topical medications. Through animal experiments, this invention has found that topical application of tyramine can alleviate skin inflammation in a mouse model of recurrent allergic contact dermatitis induced by DNFB, and significantly reduce inflammatory cells, especially CD8+, in the skin lesions. + T cell infiltration was significantly reduced; and further research revealed that after the initial inflammation, skin CD8... + The long-term survival of tissue-resident memory T cells was significantly inhibited, and tyramine is expected to become a therapeutic drug for allergic contact dermatitis, providing a new approach for the clinical treatment and prevention of recurrence of allergic contact dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to the use of tyramine in the preparation of drugs for the prevention and / or treatment of contact dermatitis. Background Technology

[0002] Allergic contact dermatitis (ACD) is a delayed-type (type IV) hypersensitivity skin disease caused by specific exogenous antigens. Its core pathogenesis is closely related to the body's immune memory of the sensitizer and T-cell-mediated inflammatory responses. When the skin is repeatedly exposed to haptens such as nickel, fragrances, preservatives, or dyes, these substances bind to skin proteins to form complete antigens, which are presented by Langerhans cells to specific T cells generated from draining lymph nodes. Upon re-exposure to the same substance, sensitized effector T cells are rapidly activated, releasing pro-inflammatory factors such as IFN-γ, inducing keratinocyte apoptosis and sponging, thus forming the pathological basis of the disease. Clinically, ACD presents as symmetrical erythema, papules, vesicles, and intense itching at the contact site.

[0003] Although the management principle emphasizes "prevention is better than cure," with the primary measure being to identify and avoid allergens through patch testing, in the modern industrialized environment, it is extremely difficult to completely avoid some core allergens (such as fragrances and preservatives widely found in personal care products, and nickel salts in metal products). Due to the ubiquitous nature of these allergens, patients are often frequently exposed unintentionally, leading to a vicious cycle of chronic and recurrent inflammatory responses, placing a significant burden on patients' daily lives.

[0004] Currently, mild to moderate ACD patients mainly rely on topical corticosteroids or calcineurin inhibitors for intervention, while severe patients require short-term systemic medication. Although existing therapies can relieve acute symptoms, long-term use of hormones carries the risk of side effects such as skin atrophy and telangiectasia. More importantly, the long-term presence of tissue-resident memory T (Trm) cells in the dermis allows for rapid inflammatory outbreaks even when triggered by trace amounts of allergens. Therefore, given the limited effectiveness of conventional avoidance strategies and the limitations of existing drug efficacy, in-depth exploration of novel topical drug targets targeting T cell activation, chemokine receptors, or JAK-STAT signaling pathways is of urgent scientific value and practical significance for improving ACD prognosis and overcoming clinical treatment challenges. Summary of the Invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide the use of tyramine in the preparation of a medicament for the prevention and / or treatment of contact dermatitis, said medicament being able to alleviate dermatitis symptoms and prevent disease recurrence.

[0006] The objective of this invention is achieved through the following technical solution: This invention provides the use of tyramine in the preparation of medicaments for the prevention and / or treatment of contact dermatitis.

[0007] Preferably, the contact dermatitis includes allergic contact dermatitis; the allergic contact dermatitis includes recurrent allergic contact dermatitis.

[0008] Preferably, the drug is used for topical skin administration.

[0009] Preferably, the effects of the drug include at least one of the following: (1) Relieves dermatitis symptoms; (2) Improves pathological damage to skin tissue; (3) Improve the immune microenvironment of the skin lesion site.

[0010] Preferably, the relief of dermatitis symptoms includes: reducing the dermatitis score; the reduction of the dermatitis score includes: reducing the dryness score, reducing the erythema score, reducing the scratch score, and reducing the swelling score, or any two or more of these.

[0011] Preferably, the improvement of skin tissue pathological damage includes: reducing epidermal thickening and reducing dermal inflammatory cell infiltration, or both.

[0012] Preferably, the improvement of the immune microenvironment at the skin lesion site includes: reducing the total number of immune cells, reducing the proportion of T cells, and reducing CD8+ at the skin lesion site. + CD69 + CD103 + The accumulation of one or more of the tissue-resident memory T cells.

[0013] This invention provides tyramine in the preparation of drugs for inhibiting CD8 in the skin. + Application in drugs that promote the accumulation of tissue-resident memory T cells.

[0014] Preferably, the drug can reduce CD8+ in skin lesions during the remission phase of allergic contact dermatitis. + The number of tissue-resident memory T cells.

[0015] This invention provides a medicament for treating contact dermatitis, comprising tyramine and a pharmaceutically acceptable carrier.

[0016] The beneficial effects of this invention are: This invention provides the use of tyramine in the preparation of medicaments for the prevention and / or treatment of contact dermatitis. Addressing the treatment challenges of contact dermatitis patients, such as difficulty avoiding allergens, frequent relapses, and limited choices of topical medications, this invention, through animal experiments, has found that topical application of tyramine can alleviate skin inflammation in a mouse model of recurrent allergic contact dermatitis induced by DNFB, and significantly reduce inflammatory cells, particularly CD8+, in the skin lesions. + T cell infiltration was significantly reduced; and further research revealed that after the initial inflammation, skin CD8... + The long-term survival of tissue-resident memory T cells was significantly inhibited, and tyramine is expected to become a therapeutic drug for allergic contact dermatitis, providing a new approach for the clinical treatment and prevention of recurrence of allergic contact dermatitis. Attached Figure Description

[0017] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0018] Figure 1 A schematic diagram of the complete experimental timeline for the establishment of a DNFB-induced recurrent allergic contact dermatitis-like mouse model and tyramine administration intervention; Figure 2 Figure showing the phenotype and evaluation results of mouse skin tissue; Figure 3 Statistical graphs of various aspects of mouse dermatitis scores; Figure 4 Image showing the results of H&E staining and quantitative histological analysis; Figure 5 Representative point plots / contour plots of the flow cytometry gating strategy for immune cell subsets in recurrent skin lesions of mice with DNFB-induced recurrent allergic contact dermatitis; Figure 6 A graph showing the quantitative statistical results of flow cytometry analysis of immune cell subsets in recurrent skin lesions of mice; Figure 7 To detect CD8+ in mouse skin lesions during the regression phase using flow cytometry + Image showing the results of tissue-resident memory T cells. Detailed Implementation

[0019] This invention provides the use of tyramine in the preparation of medicaments for the prevention and / or treatment of contact dermatitis. As an optional embodiment of this invention, the contact dermatitis includes allergic contact dermatitis; the allergic contact dermatitis includes recurrent allergic contact dermatitis. As an optional embodiment of this invention, the medicament is used for topical skin administration. In this invention, the concentration of tyramine in the medicament is 16.7~33.3 mg / mL; the unit dose of the medicament can be 20 μL / dose.

[0020] As an optional embodiment of the present invention, the effects of the drug include at least one of the following: (1) alleviating dermatitis symptoms; (2) improving pathological damage to skin tissue; (3) improving the immune microenvironment of the lesion site. As an optional embodiment of the present invention, alleviating dermatitis symptoms includes: reducing dermatitis score; the reduction of dermatitis score includes: reducing dryness score, reducing erythema score, reducing scratch score, and reducing swelling score, or any two or more of these. As an optional embodiment of the present invention, improving pathological damage to skin tissue includes: reducing epidermal thickening and reducing dermal inflammatory cell infiltration, or any two of these. As an optional embodiment of the present invention, improving the immune microenvironment of the lesion site includes: reducing the total number of immune cells, reducing the proportion of T cells, and reducing CD8+ at the lesion site. + CD69 + CD103 + The accumulation of one or more of the tissue-resident memory T cells.

[0021] This invention discloses the use of tyramine in the preparation of drugs for the prevention and / or treatment of allergic contact dermatitis, which works by inhibiting immune cell infiltration and CD8+ at the skin lesion site. + The accumulation of resident memory T cells significantly reduces dermatitis symptoms, improves skin tissue pathological damage, and reduces the risk of disease recurrence, providing a safe and effective new option for the prevention and treatment of allergic contact dermatitis, especially recurrent cases.

[0022] In this invention, the tyramine can effectively reduce the dermatitis scores of mice with allergic contact dermatitis, including dryness, erythema, scratches and swelling scores, improve skin phenotype and significantly alleviate dermatitis symptoms.

[0023] In this invention, the tyramine can significantly reduce epidermal thickening and decrease dermal inflammatory cell infiltration.

[0024] In this invention, the tyramine can significantly reduce CD45 in skin lesions. + The total number of infiltrating immune cells improves the immune microenvironment at the site of skin lesions and reduces immune cell infiltration.

[0025] In this invention, the tyramine can significantly reduce the proportion of T cells at the skin lesion site, inhibit their massive proliferation in recurrent inflammation, and suppress the proliferation of pathogenic T cells.

[0026] In this invention, the tyramine can significantly reduce CD8 in skin lesions. + CD69 + CD103 + The proportion and absolute number of resident memory T cells in the tissue are reduced, and this effect is also observed during the inflammation resolution phase, fundamentally lowering the immune basis for disease recurrence and reducing CD8+. +Accumulation of tissue-resident memory T cells.

[0027] The tyramine described in this invention is administered topically through the skin. In the embodiments of this invention, a unit dose of 20 μL / time and a concentration of 33.3 mg / mL were sufficient to achieve significant therapeutic effects in a mouse model of allergic contact dermatitis. The results of the embodiments of this invention show that tyramine has no significant effect on the basal immune cell levels in the skin of normal mice, indicating that topically administered tyramine is safe and does not affect the normal immune homeostasis of the skin.

[0028] This invention provides tyramine in the preparation of drugs for inhibiting CD8 in the skin. + Application in drugs that promote the accumulation of tissue-resident memory T cells. As an optional embodiment of the invention, the drug can reduce CD8+ in skin lesions during the resolution phase of allergic contact dermatitis. + The number of tissue-resident memory T cells. In this invention, the drug is used to reduce CD8+ retention at the skin lesion site. + The proportion of tissue-resident memory T cells to living cells and / or the absolute number of tissue cells.

[0029] This invention provides a medicament for treating contact dermatitis, comprising tyramine and a pharmaceutically acceptable carrier.

[0030] To further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below with reference to the accompanying drawings and embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0031] The experimental instruments, animals, and materials designed according to the following technical solutions of this invention Wild-type C57BL / 6J mice were purchased from Shanghai Slack Laboratory Animal Co., Ltd., China, and housed in the animal facility of Tongji University. All mice were housed in a specific pathogen-free (SPF) environment with free access to water and food, and the lighting was artificially controlled (12 hours of light, 12 hours of darkness). All procedures were performed in accordance with the guidelines and permits of the ethics committee and the animal facility.

[0032] The experimental instruments, equipment, and consumables used are as follows: -80℃ refrigerator, Haier Corporation, China; -20℃ refrigerator, Haier Corporation, China; 4℃ refrigerator, Haier Corporation, China; Ice maker, Panosonic Corporation, Japan; Vortex shaker, IKA Corporation, Germany; Electronic balance, Mettler Corporation, Switzerland; 96-well qPCR instrument, Bio-rad Corporation, USA; PCR 96-well plate, Bio-rad Corporation, USA; Large centrifuge, Eppendorf Corporation, Germany; Low-temperature benchtop centrifuge, Eppendorf Corporation, Germany; Room temperature benchtop centrifuge, Eppendorf Corporation, Germany; PCR instrument, Bio-rad Corporation, USA; 1mL / 50mL syringe, Wei Haijierui Medical Products Co., Ltd.; Ophthalmic scissors, Shanghai Jinzhong Medical Instrument Co., Ltd.; 10cm ophthalmic forceps, Shanghai Jinzhong Medical Instrument Co., Ltd.; Metal bath, Eppendorf GmbH (Germany); 0.22μm filter, Guangzhou Jete Biofiltration Co., Ltd.; Acetone, Sinopharm Chemical Reagent Co., Ltd.; Olive oil, Shanghai Aladdin Biochemical Technology Co., Ltd.; 2,4-dinitrofluorobenzene, Sigma-Aldrich; Sterile enzyme-free water (high-temperature and high-pressure sterilized deionized water), Invitrogen (USA); 4% paraformaldehyde, Wuhan Saiweier Biotechnology Co., Ltd.; Phosphate-buffered saline (Phosphate) Buffered saline (PBS, 10×), Shanghai Sangon Biotech Co., Ltd.; Fetal bovine serum (FBS), Gibco, USA; APC-conjugated-CD45 antibody, BioLegend, USA; Percp-cy5.5-conjugated-CD3 antibody, BioLegend, USA; BV605-conjugated-CD4 antibody, BioLegend, USA; FITC-conjugated-CD8 antibody, BioLegend, USA; PE-conjugated-CD69 antibody, BioLegend, USA; BV786-conjugated-CD103 antibody, BioLegend, USA; SYTOX™ Blue Dead Cell Stain, Thermo Fisher Scientific, USA; Fc receptor blocker, Thermo Fisher Scientific, USA.

[0033] Example 1 1. DNFB-induced allergic contact dermatitis-like mouse model like Figure 1As shown, 7-week-old female C57BL / 6 mice were used as experimental subjects. On day -5, 25 μL of 0.15% DNFB was applied to the left ear to sensitize the mice. On day 0, 25 μL of 0.15% DNFB was applied to the left ear to challenge sensitization, while 25 μL of control solvent (acetone: olive oil = 4:1) was applied to the right ear to establish a DNFB-induced allergic contact dermatitis-like mouse model. On day 27, anti-CD8a monoclonal antibody was injected intravenously. On days 30, 32, and 34, 25 μL of 0.05% DNFB was applied to the skin of both ears to establish a recurrent allergic contact dermatitis-like mouse model.

[0034] 2. Mouse grouping and drug treatment A mouse model of allergic contact dermatitis induced by DNFB was divided into a control group and a tyramine group. Mice in the tyramine group received 20 μL of 33.3 mg / mL tyramine applied to the skin of both ears daily from day 10 to 21. Mice in the control group received an equal volume of solvent (tyramine removed from the tyramine formulation) for treatment, with the remaining treatments the same as described in section 1 above. Specific methods are as follows: Figure 1 As shown. After the experiment, skin tissue samples were collected at predetermined time points and embedded in paraffin for later use.

[0035] The specific solvent formulation consists of 70% polyethylene glycol 300 (PEG300) and 30% ethanol (Ethanol). PEG300 was purchased from MedChemExpress (catalog number HY-Y0873), and ethanol was purchased from Sangon Biotech (catalog number A500737). Tyramine (4-hydroxyphenylethylamine); CAS: 51-67-2, molecular formula C8H 11 NO.

[0036] 3. Allergic contact dermatitis score in mice (1) Evaluation indicators ①Dryness: The degree of dryness of the skin; ② Erythema: The degree of redness of the skin; ③ Excoriation: The condition of the skin being scratched; ④ Edema: Thickening of the ear.

[0037] (2) Scoring criteria ① A 4-level scoring system (0-3 points) is adopted, with each parameter scored independently; ②The scoring criteria are shown in Table 1 below.

[0038] Table 1 Scoring Criteria

[0039] (3) Evaluation methods ① Assessment process: The mice were placed in an observation cage and kept quiet. The skin lesion area was recorded using a camera. Two trained researchers scored the mice independently, and the average score was taken as the final score. ② Scoring calculation: Calculation formula: Dermatitis score = dryness score + erythema score + scratch score + swelling score. Total score range: 0-12 points. The higher the score, the more severe the condition.

[0040] 4. Assessment of ear thickening in mice Mice were placed in observation cages and kept quiet. Ear thickness was measured using calipers by two trained researchers independently. The average value was taken, and the percentage increase relative to baseline was calculated.

[0041] 5. HE staining (1) Dewaxing and hydration: The paraffin-embedded skin tissue samples from step 2 were immersed in xylene to dissolve and remove the paraffin. The skin tissue sections were then gradually transitioned from an organic solvent environment to an aqueous environment by sequentially passing through a gradient of ethanol (100%→95%→80%→70%).

[0042] (2) Hematoxylin staining: Immerse the hydrated skin tissue sections in hematoxylin staining solution for five minutes. After staining, rinse off the excess staining solution with running water.

[0043] (3) Differentiation: Skin tissue sections were briefly treated with 1% hydrochloric acid ethanol to wash away the excessive and loosely bound hematoxylin on the cell nuclei, making the nuclear staining clearer and more distinct.

[0044] (4) Blueing / Blueing: Place the skin tissue slices in a weak alkaline solution (such as tap water, warm water or saturated lithium carbonate solution) to make the acidified hematoxylin reappear blue-purple and enhance the contrast.

[0045] (5) Eosin staining: Immerse the skin tissue section in eosin staining solution for one minute. After staining, rinse gently with running water.

[0046] (6) Dehydration and clearing: The skin tissue sections were dehydrated by sequentially passing through a gradient of ethanol (70%→80%→95%→100%). The sections were then treated with xylene to make the tissue clear, which facilitated mounting and microscopic observation.

[0047] (7) Mounting: Add neutral resin or other mounting agent to the skin tissue section, cover with a coverslip, and make a permanent slide specimen.

[0048] 6. Histological evaluation (1) Dermal inflammatory cell infiltration ① Randomly select a 100μm×100μm region in the dermis of the HE-stained image and count the number of cell nuclei within the region; ② Three fields of view were randomly selected from each skin tissue section, and three regions were analyzed in each field of view. The average nuclear density (number of nuclei / 100 μm) was calculated. 2 ).

[0049] ③ Magnification: 100×; ④ Analysis software: Image J 1.52a.

[0050] ⑤ The data analysis was performed using a double-blind method, with two researchers completing the analysis independently and then averaging the results.

[0051] 7. Flow cytometry (1) Cut the mouse skin tissue into small pieces, put it into digestive enzymes, and digest it at 37°C for 45-55 minutes by rotating. (2) After digestion, the tissue was mixed and passed through a cell sieve (40μm). The remaining large pieces of tissue were ground. Fetal bovine serum (FBS) was added to stop digestion. Pre-cooled PBS was added to about 20mL. Skin cells were obtained by centrifugation at 500g for 5 minutes. (3) Discard the supernatant, add 100 μL of staining buffer to resuspend, transfer to a round-bottom 96-well plate, centrifuge at 500g for 5 minutes, and discard the supernatant; (4) The receptor blocker was diluted with staining buffer at a volume ratio of 1:50, and 100 μL was resuspended in each well and incubated at room temperature in the dark for 10 minutes. (5) Add the premixed antibody to each well, mix well, and incubate at 4°C in the dark for 30 minutes; (6) Add pre-cooled PBS, mix well, centrifuge the cells at 500g for 5 minutes at 4°C, and discard the supernatant; (7) Add 200 μL PBS, resuspend and mix, transfer to a flow cytometer, further dilute, add SYTOX™ Blue Dead Cell Stain at a volume ratio of 1:1000 and incubate for 5 minutes, then perform flow cytometry analysis.

[0052] 8. Experimental Results (1) Phenotypic and evaluation results of mouse skin tissue as follows Figure 2 As shown.

[0053] Figure 2 The results show the skin phenotypes of mice in the control and tyramine groups. Among them, OOA-DNFB: control group (only the DNFB-induced primary inflammation model was established); DNFB-DNFB: DNFB-induced recurrent allergic contact dermatitis model group; Vehicle: solvent control; Tyramine: tyramine administration group, the same below; A shows the skin phenotypes of the control and tyramine mice; B shows the increase in ear thickness of mice (specific values ​​are shown in Tables 2 and 3); C shows the severity index assessment results of allergic contact dermatitis in mice. Figure 2Day 0 in the study was the time when DNFB stimulation was restarted (i.e., day 30 of the experiment). Skin phenotypes of the control group and tyramine mice were photographed on day 36. The severity index of allergic contact dermatitis in mice was assessed on day 36.

[0054] Table 2. Increase in ear thickness in mice in the DNFB-induced primary allergic contact dermatitis model group.

[0055] Table 3. Increase in ear thickness in mice in the DNFB-induced recurrent allergic contact dermatitis model group.

[0056] from Figure 2 As can be seen, the tyramine group showed a significant reduction in recurrent erythema, skin thickening, and ear swelling. The tyramine group's score was lower than that of the control group, indicating that tyramine can alleviate skin inflammation in a mouse model of recurrent allergic contact dermatitis induced by DNFB.

[0057] The specific changes in the scores of various indicators of allergic contact dermatitis in mice are as follows: Figure 3 As shown.

[0058] Depend on Figure 3 It can be seen that there were no significant differences in dryness score, erythema score, scratch score and swelling score between the Vehicle and Tyramine groups in the OOA-DNFB group. However, in the DNFB-DNFB group, tyramine treatment significantly reduced the swelling score and erythema score during recurrent inflammation, but had no significant effect on the dryness score and scratch score.

[0059] (2) HE staining results are as follows Figure 4 As shown.

[0060] Mouse skin samples collected on day 36 of the experiment (48 hours after DNFB restimulation) were stained with hematoxylin and eosin (HE). The results are as follows: Figure 4 As shown, A is an H&E staining image, B is an image of immune cell infiltration, and C is an image of epidermal thickness. From... Figure 4 The results show that tyramine significantly improved epidermal thickening and inflammatory cell infiltration in mice, further demonstrating that tyramine can alleviate skin inflammation in a DNFB-induced recurrent allergic contact dermatitis-like mouse model.

[0061] (3) Flow cytometry results are as follows Figures 5-6 As shown.

[0062] Figures 5-6 The image shows the flow cytometry results of immune cell subsets in recurrent skin lesions of mice (48 hours after DNFB restimulation, day 36 of the experiment). Figure 7 The image shows the flow cytometry results of T cell subsets in mouse skin lesions during the regression phase (sampled on day 30 of the experiment, before the second DNFB stimulation).

[0063] Figure 5 Representative point plots / contour plots of the flow cytometry gating strategy for immune cell subsets in recurrent skin lesions of mice with DNFB-induced recurrent allergic contact dermatitis.

[0064] Figure 6 A graph showing the quantitative statistical results of flow cytometry; B: CD45 + Total immune cells; C: CD3 + T lymphocytes; D:CD8 + T tissue-resident memory T cells.

[0065] Figure 7 To detect CD8+ in mouse skin lesions during the regression phase using flow cytometry + Image of tissue-resident memory T cells; A: CD8+ lesions in the regression phase + Representative contour plot of T cell flow cytometry gating strategy; B: CD8 + Quantitative statistical scatter-bar plot of T cells.

[0066] Depend on Figure 5 It can be obtained that total immune cells (CD45) + Percentage: OOA-DNFB (initial model): Vehicle 1.72%, Tyramine 1.76%, almost no difference between the two groups; DNFB-DNFB relapse model: Vehicle group 14.1% (massive infiltration of immune cells); Tyramine group decreased to 3.41%. This indicates that DNFB relapse stimulation resulted in significant infiltration of total immune cells in the skin; Tyramine treatment significantly reduced the infiltration of total immune cells in the lesion site.

[0067] T lymphocytes (CD45) + CD3 + CD11b - ) occupying CD45 + Immune cell proportions: OOA-DNFB: Vehicle 54.7%, Tyramine 48.9%, baseline levels are similar; DNFB-DNFB relapse model: Vehicle 52.5%, Tyramine 45.4%. In the relapse model, total CD45... + When cells are downregulated by tyramine, the proportion of T cells among immune cells decreases only slightly, while the proportion of T cells among all living cells and their absolute number both decrease significantly.

[0068] CD8 + T cells (CD3) + CD8+ OOA-DNFB: Vehicle 2.82%, Tyramine 3.26%, low baseline levels; DNFB-DNFB model Vehicle: 42.0%; Tyramine group: 25.1%. CD8 levels after relapse modeling. + T cells were significantly amplified; tyramine significantly downregulated CD8 in skin lesions. + T cell ratio.

[0069] CD8 + CD69 + CD103 + Tissue-resident memory T cells: CD103 + CD69 + This is the gold standard phenotype of skin tissue-resident memory T cells, mediating contact dermatitis recurrence. In the OOA-DNFB group, this cell population is almost absent; in the DNFB-DNFB Vehicle group, the cell population is significantly enlarged; and in the Tyramine group, the cell population is significantly reduced in size. The recurrence model shows a large accumulation of CD8+ cells in the skin. + T; Tyramine can inhibit skin CD8 + Accumulation of tissue-resident memory T cells.

[0070] Figure 5 Flow cytometry was used to detect immune cell subsets in mouse skin lesions. OOA-DNFB group mice skin CD45 + Total immune cells, CD8 + T and CD8 + CD69 + CD103 + The baseline level of tissue-resident memory T cells was low, and tyramine treatment had no significant effect on basal immune cell infiltration. After establishing the DNFB-DNFB recurrent contact dermatitis model, CD45 levels in the skin lesions of mice in the Vehicle solvent control group were [data missing]. + Total immune cell infiltration was significantly increased, CD8 + T cells and pathogenic CD8 + CD69 + CD103 + T cells were abundant; compared with the Vehicle group, tyramine treatment significantly reduced CD45 in the lesion area. + Total immune cell infiltration, while CD8 downregulation + T cell ratio and inhibition of skin CD8 + Accumulation of T cells.

[0071] Repeated stimulation with DNFB successfully induced a large infiltration of immune cells into the skin and induced CD8. + CD69 + CD103 +The accumulation of tissue-resident memory T cells is the cellular basis of recurrent allergic contact dermatitis. Topical administration of tyramine can inhibit the infiltration of immune cells at recurrent skin lesions, especially inhibiting skin CD8. + Accumulation of tissue-resident memory T cells.

[0072] Figure 6 The B-side displays CD45. + The proportion and absolute number of immune cells among all living cells were significantly reduced; C showed a significant reduction in both the proportion and absolute number of T cells among all living cells; D showed a significant reduction in CD8+. + The proportion and absolute number of Trm cells among all living cells were significantly reduced. CD45 levels in the skin of OOA-DNFB control mice were also significantly reduced. + Total immune cells, T lymphocytes and CD8 + T cells were all at low levels, and tyramine treatment had no significant effect on the proportion or absolute number of these immune cells (ns). After establishing the DNFB-DNFB recurrent contact dermatitis model, CD45 levels in the skin lesions of mice in the Vehicle solvent control group were [data missing]. + Total immune cells, T lymphocytes, and CD8 + The percentage of T cells and the absolute number of cells per ear were both significantly increased; compared with the Vehicle group, tyramine treatment significantly downregulated CD45 in the skin lesions. + Immune cells, T cells, and CD8 + The proportion and absolute number of T cells (** P<0.01, **** P<0.0001).

[0073] Figure 7 In the middle A region, CD8 is present in the skin lesions during the regression phase in mice. + Flow cytometry gating strategy of Trm cells, B-cells show CD8 + The proportion and absolute number of Trm cells among all living cells were significantly reduced. In the remission phase of lesions, both groups of CD8... + The proportions of T cells expressing CD69 and CD103, characteristic markers of skin tissue-resident memory T cells, showed almost no difference, indicating that CD8+ can survive long-term in tissues. + The T cells still exhibit the skin tissue-resident memory T cell phenotype. Meanwhile, the overall skin local CD8... + The percentage of Trm and the total absolute number of cells in each ear decreased significantly after tyramine treatment, suggesting that tyramine's target is to induce local CD8+ oxidase activity in the skin. + The residence of Trm cells in the skin is suppressed.

[0074] This indicates that tyramine can reduce CD8 levels in mice after contact dermatitis. + Long-term residence of Trm cells can reduce recurrent inflammation.

[0075] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of tyramine in the preparation of medicaments for the prevention and / or treatment of contact dermatitis.

2. The application according to claim 1, characterized in that, The contact dermatitis includes allergic contact dermatitis; the allergic contact dermatitis includes recurrent allergic contact dermatitis.

3. The application according to claim 1 or 2, characterized in that, The drug is for topical skin administration.

4. The application according to claim 1, characterized in that, The effects of the drug include at least one of the following: (1) Relieves dermatitis symptoms; (2) Improves pathological damage to skin tissue; (3) Improve the immune microenvironment of the skin lesion site.

5. The application according to claim 4, characterized in that, The relief of dermatitis symptoms includes: reducing the dermatitis score; the reduction of the dermatitis score includes: reducing the dryness score, reducing the erythema score, reducing the scratch score, and reducing the swelling score, or any two or more of these.

6. The application according to claim 4, characterized in that, The improvement of skin tissue pathological damage includes: reducing epidermal thickening and reducing dermal inflammatory cell infiltration, or both.

7. The application according to claim 4, characterized in that, The improvement of the immune microenvironment at the skin lesion site includes: reducing the total number of immune cells, reducing the proportion of T cells, and reducing CD8+ at the skin lesion site. + CD69 + CD103 + One or more of the following: the accumulation of tissue-resident memory T cells.

8. Tyramine in the preparation of drugs for inhibiting CD8 in the skin + Application in drugs that promote the accumulation of tissue-resident memory T cells.

9. The application according to claim 8, characterized in that, The drug can reduce CD8+ levels in skin lesions during the remission phase of allergic contact dermatitis. + The number of tissue-resident memory T cells.

10. A medicament for treating contact dermatitis, characterized in that, This includes tyramine and pharmaceutically acceptable carriers.